<DOC>
	<DOCNO>NCT02419495</DOCNO>
	<brief_summary>Objectives : Primary Objective : To establish safety tolerability Selinexor give combination standard chemotherapy regimen . Secondary Objectives : To determine disease control progression free survival Selinexor administer standard chemotherapy treatment . Exploratory Objectives : To determine correlation translational biomarkers To compare serial assessment mutation status biopsy obtain baseline progression clinical response combination therapy</brief_summary>
	<brief_title>Phase IB Selinexor Combination With Standard Chemotherapy Patients With Advanced Malignancies</brief_title>
	<detailed_description>This open label , single center Phase IB combination therapy study metastatic locally advanced cancer . The addition Selinexor multiple standard chemotherapy regimen test parallel . Two type patient may enrol study : ( 1 ) advance staged cancer patient either unresponsive relapse follow prior standard therapy know effective therapy ; OR ( 2 ) advance stage cancer patient standard chemotherapy treatment Selinexor add consider appropriate acceptable therapy . Patients meet criterion may case receive prior chemotherapy . Study Groups : If participant find eligible take part study , doctor decide part study base type tumor . The study doctor discus participant . - If participant Group A , receive selinexor carboplatin . - If participant Group B , receive selinexor paclitaxel . - If participant Group C , receive selinexor eribulin . - If participant Group D , receive selinexor , doxorubicin , cyclophosphamide . - If participant Group E , receive selinexor , carboplatin , paclitaxel . - If participant Group F , receive selinexor , carboplatin , pemetrexed . - If participant Group G , receive selinexor topotecan . - If participant Group H , receive selinexor combination FOLFIRI . - If participant Group I , receive selinexor combination irinotecan . - If participant Group J , receive selinexor combination XELOX . - If participant Group K , receive selinexor combination olaparib . - If participant Group L , receive selinexor combination pembrolizumab . Up 470 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Folic Acid Antagonists</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm malignant neoplasm ( include hematological malignancy brain tumor ) untreated previously treat require treatment . Patients must refractory , intolerant , establish therapy know provide clinical benefit condition . 2 . Patients must fail prior standard curative chemotherapy disease . Subjects must fail , intolerant , ineligible potentially curative approve treatment , irrespective line therapy . 3 . Patients must either measurable disease ( RECIST 1.1 ) evaluable disease ( nonmeasurable lesion ) outside irradiated field CT/MRI . 4 . Age &gt; /= 18 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 6 . The patient must recover prior major surgery . The major surgery must perform least 4 week prior consent date . 7 . Adequate hematologic function define : platelet &gt; /=125 x 10^9/L ( For Arm L Pembrolizumab , platelets &gt; /= 100 x 10^9/L ) , hemoglobin &gt; /= 10 g/dL ( For Arm L Pembrolizumab , hemaglobin &gt; /= 9 g/dL ) , ANC &gt; /= 1.5 x 10^9/L , WBC &gt; /= 3 x 10^9/L , Albumin &gt; /= 3 g/dL . Transfusions growth factor allow . 8 . Adequate liver function define : Alanine transaminase ( ALT ) &lt; /= 2 x upper normal limit ( ULN ) ( In expansion cohort , patient know liver involvement may ALT &lt; /= 5 x ULN ) , Aspartate aminotransferase ( AST ) &lt; /=2 x ULN ( In expansion cohort , patient know liver involvement may AST &lt; /= 5 x ULN ) , Alkaline phosphatase &lt; 4 x ULN , Total Bilirubin &lt; /=2 x ULN ( In expansion cohort , patient Gilbert 's syndrome [ hereditary indirect hyperbilirubinemia ] must total bilirubin &lt; /= 3 x ULN ) . 9 . Renal function define calculate measured glomerular filtration rate ( GFR ) &gt; /=30 mL/min . For Arm F Carboplatin Pemetrexed , GFR &gt; /=45 mL/min . 10 . The patient recover Grade &lt; /= 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.03 ( NCICTCAE v4.03 ) effect recent surgery , radiotherapy , chemotherapy , hormonal therapy , targeted therapy , exception alopecia . The exception effect allow lab value &lt; /= Grade 2 specify elsewhere inclusion criterion . 11 . Life expectancy least 12 week . 12 . Able swallow retain oral medication . 13 . Patients must give informed consent accord rule regulation individual participate site . 14 . Negative serum pregnancy test woman childbearing potential within 7 day first dose treatment patient childbearing potential must agree use effective contraception during/after 3 month post dose . A woman childbearing potential define premenopausal female capable become pregnant . This include woman oral , injectable mechanical contraception ; woman single woman whose male sexual partner vasectomize whose male sexual partner receive utilizing mechanical contraceptive device . 15 . If Arm D ( Doxorubicin Cyclophosphamide ) , leave ventricular ejection fraction ( LVEF ) &gt; /= 50 % measure echocardiogram ( ECHO ) within 4 week prior study drug administration . 1 . Evidence complete partial bowel obstruction . 2 . Patients primary CNS tumor CNS tumor involvement . However , patient metastatic CNS tumor may participate study patient : &gt; 4 week prior therapy completion ( include radiation and/or surgery ) ; Clinically stable respect CNS tumor time study entry ; Not receive steroid therapy treat CNS tumor CNS tumor involvement ; Not receive anticonvulsive medication ( start brain metastasis ) . 3 . Need Total Parenteral Nutrition . 4 . Prior treatment agent target Exportin . 5 . Allergic Selinexor chemotherapy intend receive . 6 . Pregnancy lactation . 7 . Radiation ( except plan ongoing palliative radiation bone outside region measurable disease ) &lt; /= 3 week prior study drug administration date . 8 . Chemotherapy , immunotherapy systemic anticancer therapy &lt; /=3 week prior study drug administration date . 9 . Diagnosis recurrence invasive cancer present cancer within 3 year ( except basal squamous cell carcinoma skin definitively treat ) . 10 . Major surgery within four week consent date . 11 . Unstable cardiovascular function : Symptomatic ischemia ( chest pain cardiac origin ) , Uncontrolled clinically significant conduction abnormality ( e.g . ventricular tachycardia antiarrhythmic exclude 1st degree AV block asymptomatic LAFB/ RBBB exclude ) , Congestive heart failure ( CHF ) NYHA Class &gt; /= 3 , Myocardial infarction ( MI ) within 3 month consent date . 12 . Uncontrolled active infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose . Active infection concurrent treatment acceptable patient clinically stable . 13 . Significantly diseased ( determine PI treat physician ) obstruct gastrointestinal tract uncontrolled vomit diarrhea . 14 . Treatment investigational anticancer study drug within 3 week prior study drug administration date . 15 . Concurrent therapy approve investigational anticancer therapeutic . 16 . Medical , psychological social condition may interfere patient 's participation study evaluation study result 17 . Men whose partner woman childbearing potential , ( i.e . biologically able conceive ) , employ two form highly effective contraception . Highly effective contraception ( e.g . male condom spermicide , diaphragm spermicide , intrauterine device ) must use sex study must continue 3 month end study treatment . Women childbearing potential define sexually mature woman surgically sterile naturally postmenopausal least 12 consecutive month ( e.g. , menses time precede 12 consecutive month ) . 18 . If Arm D ( Doxorubicin Cyclophosphamide ) , patient prior cumulative doxorubicin dose &gt; /= 260 mg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>Malignant neoplasm</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Eribulin</keyword>
	<keyword>E7389</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>LY231514</keyword>
	<keyword>Alimta</keyword>
	<keyword>MTA</keyword>
	<keyword>Multitargeted Antifolate</keyword>
	<keyword>NSC-698037</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>Selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Camptosar</keyword>
	<keyword>5-FU</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>5-Fluorouracil</keyword>
	<keyword>Adrucil</keyword>
	<keyword>Efudex</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Olaparib</keyword>
	<keyword>Lynparza</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Keytruda</keyword>
	<keyword>MK-3475</keyword>
	<keyword>SCH-900475</keyword>
</DOC>